Goals and Objectives
The solubility behavior of drugs remains one of the most challenging aspects in formulation development for BCS II and IV APIs. This program will provide a fundamental understanding and the latest update on solubility enhancement technologies. Day one of the program will focus on drug solubility in terms of BCS, alteration and prediction. Day two of the program is designed to provide in-depth review on liquid formulations. Day three of the program will focus on solid formulations. The final day of the program will cover enabling technologies for solubility enhancement, such as supercritical fluid processing, spray drying, hot melt extrusion freeze drying, and QbD from both industrial and regulatory perspectives. Case studies and workshops will also be provided everyday to engage participation from the attendees.
Special Announcements
Presentations are now online and accessible from the Final Program by clicking on selected presentation titles.
Planning Committee Members
Jian-Xin Li, Ph.D., Evonik-Degussa Corporation, US,
Chair
Rainer H. Müller, Ph.D., Free University of Berlin, Germany,
Co-chair
Qiang Zhang, Ph.D., Peking University, China,
Co-chair
Susan Lum, Ph.D., Patheon Inc., Canada
Colleen E. Ruegger, Ph.D., Novartis Pharmaceuticals, US
Anil M. Salpekar, Ph.D., Solvay Pharmaceuticals, Inc., US
Duxin Sun, Ph.D., University of Michigan, US
Dave Wallick, Ph.D. The Dow Chemical Company, US
Geoff G.Z. Zhang, Ph.D. Abbott Laboratories, US
Melvin H. Weinswig, Ph.D., University of Wisconsin-Madison, US, Continuing Education